Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Senti Biosciences Inc (SNTI)

Senti Biosciences Inc (SNTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,000
  • Shares Outstanding, K 26,291
  • Annual Sales, $ 0 K
  • Annual Income, $ -52,790 K
  • EBIT $ -66 M
  • EBITDA $ -60 M
  • 60-Month Beta 2.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.43
  • Number of Estimates 2
  • High Estimate -0.23
  • Low Estimate -0.63
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +35.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.44 +65.97%
on 11/17/25
2.48 -3.63%
on 12/08/25
+0.44 (+22.56%)
since 11/07/25
3-Month
1.26 +89.68%
on 09/10/25
2.55 -6.27%
on 10/16/25
+1.07 (+81.06%)
since 09/08/25
52-Week
1.26 +89.68%
on 09/10/25
7.10 -66.34%
on 12/09/24
-3.11 (-56.55%)
since 12/06/24

Most Recent Stories

More News
Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 2.39 (+12.21%)
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 2.39 (+12.21%)
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating relapsed/refractory...

SNTI : 2.39 (+12.21%)
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 2.39 (+12.21%)
Senti Bio to Present at BioJapan

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 2.39 (+12.21%)
Senti Bio to Present at the MedInvest Biotech & Pharma Conference

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 2.39 (+12.21%)
Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 2.39 (+12.21%)
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025

Register for the three-day event here

AKTX : 0.3400 (+0.29%)
NUWE : 2.71 (+11.52%)
AIM : 1.5200 (+10.14%)
AMIX : 0.8207 (-2.88%)
SNTI : 2.39 (+12.21%)
CNSP : 7.21 (+9.24%)
NVNO : 0.3255 (-7.95%)
MBRX : 7.25 (+0.14%)
GRI : 1.35 (-34.47%)
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...

SNTI : 2.39 (+12.21%)
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Access the “What This Means” segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology...

SNTI : 2.39 (+12.21%)

Business Summary

Senti Biosciences Inc. is a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform. Senti Biosciences Inc., formerly known as Dynamics Special Purpose Corp., is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 2.87
2nd Resistance Point 2.68
1st Resistance Point 2.53
Last Price 2.39
1st Support Level 2.19
2nd Support Level 2.00
3rd Support Level 1.85

See More

52-Week High 7.10
Fibonacci 61.8% 4.87
Fibonacci 50% 4.18
Fibonacci 38.2% 3.49
Last Price 2.39
52-Week Low 1.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar